---
title: "Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence"
description: "Formulary evidence on Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence. Covers SUMMIT, PIONEER, and WO2024138005A1 example 7. 61 evidence topics quoted from 27 sources."
canonical: "https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Bezuclastinib in Nonadvanced systemic mastocytosis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 SUMMIT

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Comparison of safety and efficacy

> “comparing the safety and efficacy”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### SUMMIT Part 2 primary analysis: data cutoff

> “Data cutoff: May 22, 2025.”

Source: [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)

<a id="topic-3.1.1.2-2"></a>

###### European study participation

> “In addition, bezuclastinib, another TKI specific to D816V, is being evaluated in a study (SUMMIT) involving several European centers”

Source: [Bulai Livideanu et al. (2025)](https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03764-7)

Additional sources: [ClinicalTrials.gov NCT05186753](https://clinicaltrials.gov/study/NCT05186753)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### SUMMIT NCT05186753: study design

> “This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="topic-3.1.1.3-2"></a>

###### SUMMIT Part 2: randomization

> “randomized 2:1”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### SUMMIT Part 2: symptom-based eligibility

> “Inadequate symptom control (moderate to severe symptoms) despite ≥2 anti-mediator therapies”

Source: [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)

<a id="topic-3.1.1.4-2"></a>

###### Avapritinib-switch substudy: population

> “patients who are experiencing inadequate symptom control with avapritinib.”

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### SUMMIT Part 2: bezuclastinib dose

> “100mg every day”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="topic-3.1.1.5-2"></a>

###### SUMMIT Part 2: background therapy in both randomized groups

> “bezuclastinib+ BSC”
> “placebo+BSC”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using MS2D2 Total Symptom Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary symptom endpoint

> “24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS)”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="topic-3.1.1.6.1-2"></a>

###### Outcome-instrument validation: MS2D2

> “Test–retest reliability between screening and baseline among PGIS-stable participants indicated excellent agreement (ICC > 0.9) for all MS2D2 scores”

Source: [Marcus et al. (2026)](https://link.springer.com/article/10.1007/s11136-026-04291-z)

Additional sources: [Siebenhaar et al. (2025b)](https://epostersonline-2.s3.amazonaws.com/soho2025/soho2025.41505d6.NORMAL.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### SUMMIT Part 2: randomized treatment groups

> “n=119 bezuclastinib, n=60 placebo;”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="topic-3.1.1.7.1-2"></a>

###### SUMMIT Part 1a: enrollment

> “Part 1a of Summit enrolled 20 patients”

Source: [Blood (2023)](https://scholars.duke.edu/publication/1664410)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Biomarker responder analysis: intention-to-treat handling of missing observations

> “ITT population: patients missing data at baseline and/or week 24 are treated as nonresponders for this analysis.”

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="topic-3.1.1.7.2-2"></a>

###### Exploratory individual-symptom analysis: covariates and multiplicity

> “Unadjusted P values based on ANCOVA model adjusted for TSS baseline and tryptase level, no multiplicity adjustment.”

Source: [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### SUMMIT Part 2: withdrawal before treatment

> “One patient withdrew consent and did not receive treatment.”

Source: [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/)

<a id="topic-3.1.1.8.1-2"></a>

###### Avapritinib-switch extension: anticipated results

> “preliminary results expected by end of 2026.”

Source: [Cogent Biosciences second quarter 2026 results announcement (2026)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-reports-recent-business-highlights-and-11)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### SUMMIT Part 2: baseline age

| Baseline median age in years, with range | Direct quotation |
| ---------------------------------------- | ---------------- |
| Bezuclastinib                            | “51 (24–73)”     |
| Placebo                                  | “52 (23–78)”     |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="topic-3.1.1.8.2-2"></a>

###### SUMMIT Part 2: baseline symptom burden and smoldering subtype

| Characteristic | Bezuclastinib | Placebo |
| --- | --- | --- |
| Mean baseline MS2D2 TSS | “57.1” | “52.6” |
| Participants with smoldering SM | “8” | “4” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### SUMMIT Part 2: primary endpoint, 24-week total symptom score

| Measure                       | Bezuclastinib | Placebo | Statistical significance |
| ----------------------------- | ------------- | ------- | ------------------------ |
| TSS, “mean reduction”, points | “24.3”        | “15.4”  | “p=0.0002”               |

Source: [Cogent Biosciences SUMMIT top-line results announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-top-line-results-achieving)

<a id="topic-3.1.1.8.3-2"></a>

###### SUMMIT Part 2: symptom-response endpoints at 24 weeks

| “Outcome measure”       | “Bezuclastinib” | “Placebo” | “p-value” |
| ----------------------- | --------------: | --------: | --------: |
| “≥50% reduction in TSS” |         “34.3%” |   “18.1%” |  “p=0.01” |
| “≥30% reduction in TSS” |         “65.4%” |   “38.6%” | “p<0.001” |

Source: [Cogent Biosciences SUMMIT full results announcement at ASH (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-presents-full-summit-results-bezuclastinib)

<a id="topic-3.1.1.8.3-3"></a>

###### SUMMIT Part 2: serum tryptase at 24 weeks

> “Patients reaching ≥50% reduction in serum tryptase at 24 weeks, % (n/N)”

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

| Population       |    Bezuclastinib |    Placebo | Statistical significance |
| ---------------- | ---------------: | ---------: | -----------------------: |
| “ITT population” | “87.4 (104/119)” | “0 (0/60)” |               “P<0.0001” |

Source: [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="topic-3.1.1.8.3-4"></a>

###### SUMMIT Part 2: 48-week follow-up, November 2025 cutoff

| Measure               |  Bezuclastinib |
| --------------------- | -------------: |
| “Mean change TSS (%)” | “-32.0 (-54%)” |

Source: [Cogent Biosciences SUMMIT full results announcement at ASH (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-presents-full-summit-results-bezuclastinib)

<a id="topic-3.1.1.8.3-5"></a>

###### SUMMIT Part 1b: symptom severity at 12 weeks

> “Patients treated with 100 mg bezuclastinib reported a significant reduction in total symptom severity vs. placebo at Week 12 (-23.78 vs. -9.03; p=0.0003)”

Source: [Cogent Biosciences presentation (2024)](https://investors.cogentbio.com/static-files/6c1e88e8-fd51-40f6-8b0f-dddc6ca28dc2)

<a id="topic-3.1.1.8.3-6"></a>

###### SUMMIT selected 100 mg dose and open-label extension: 12-week assessment

> “Pts treated with 100 mg bezu had reduction in MS2D2 TSS by 49.1% vs 21.1% with PBO.”

Source: [Rein et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper194551.html)

<a id="topic-3.1.1.8.3-7"></a>

###### SUMMIT Part 1: 48-week follow-up

> “MS2D2 Total Symptom Score reduced from baseline by a mean of 28.8 points and 64.6% at 48 weeks”

Source: [AAAAI (2025)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2025-Summit.pdf)

<a id="topic-3.1.1.8.3-8"></a>

###### SUMMIT Part 2: exploratory bone assessments

> “Patients receiving bezuclastinib demonstrated increased spine BMD at Week 24, while those receiving placebo showed no improvement or a decrease”

Source: [AAAAI (2026)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2026-Summit-Bone.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### SUMMIT: correlation between symptom improvement and objective disease markers

> “Symptom improvement significantly correlated with serum tryptase reduction”
> “p < 0.001, r = 0.39”

Source: [George et al. (2026)](https://www.cogentbio.com/wp-content/uploads/AAAAI-2026-Summit-Correlational.pdf)

Additional sources: [Rein et al. (2025)](https://ashpublications.org/blood/article/146/Supplement%201/80/548775/Efficacy-and-safety-results-from-the-primary); [George et al. (2025)](https://doi.org/10.1182/blood-2025-1023); [Boggs et al. (2026)](https://www.jacionline.org/article/S0091-6749%2825%2901708-7/fulltext); [Bose et al. (2026)](https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650%2826%2902411-0/fulltext)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### SUMMIT selected 100 mg dose: 12-week MC-QoL change

| Measure | Bezuclastinib 100 mg | Placebo |
| --- | --- | --- |
| Least-squares mean change from baseline | “-22.05” | “-10.71” |

Source: [Rein et al. (2024)](https://ash.confex.com/ash/2024/webprogram/Paper194551.html)

Additional sources: [Akin et al. (2026a)](https://www.jacionline.org/article/S0091-6749%2825%2901699-9/fulltext)

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### SUMMIT Part 2: selected treatment-emergent adverse events

> “hair color change (69.5% bezuclastinib vs. 5.0% placebo)”
> “ALT/AST elevations (22.0% bezuclastinib vs. 6.6% placebo; ≥Gr 3, 5.9% vs. 0%)”

Source: [Cogent Biosciences SUMMIT top-line results announcement (2025)](https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-positive-top-line-results-achieving)

<a id="topic-3.1.1.8.5-2"></a>

###### SUMMIT Part 2: treatment-related discontinuations

> “All discontinuations (5.9%) due to treatment-related AEs were due to transaminase elevations; all fully resolved.”

Source: [Rein et al. (2026a)](https://ncoda.org/nohma/2026isf-a25p25/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

SUMMIT compares bezuclastinib with placebo rather than an active KIT inhibitor. Eligibility requires inadequate symptom control despite at least two anti-mediator therapies, limiting direct applicability to less symptomatic or untreated populations. Baseline mean TSS was 57.1 versus 52.6, and the smoldering SM groups contained only 8 and 4 participants. Reported subgroup changes are within-arm estimates rather than treatment-by-subgroup interaction tests. The individual-symptom analyses report no multiplicity adjustment. Biomarker responder analyses count missing baseline or week 24 observations as nonresponse; those rules should not be assumed to describe every efficacy analysis.

Source: [MD Anderson Cancer Center](https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2021-0880.html); [Rein et al. (2026b)](https://ncoda.org/efficacy_and_safety_results_pos/); [Cogent Biosciences presentation (2025)](https://investors.cogentbio.com/static-files/64526478-fe1c-4965-8329-5918e4aa5d78)

<a id="heading-3.1.2"></a>

#### 3.1.2 PIONEER

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Comparator trial objective

> “efficacy and safety of avapritinib versus placebo”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Long-term follow-up: data cutoff

> “February 21, 2025”

Source: [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Randomized comparison: masking and control

> “randomized, double-blind, placebo-controlled”

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

<a id="topic-3.1.2.3-2"></a>

###### Long-term extension design

> “open-label part 3 is ongoing with up to 5 years of follow-up.”

Source: [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Symptom severity at enrollment

> “moderate to severe ISM”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="topic-3.1.2.4-2"></a>

###### Minimum baseline total symptom score

| Eligibility measure | Threshold |
| --- | --- |
| TSS | “≥28” |

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Avapritinib dose for ISM

> “The recommended dosage of AYVAKIT is 25 mg orally once daily in patients with ISM.”

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

<a id="topic-3.1.2.5-2"></a>

###### Background treatment in both groups

> “best supportive care”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using ISM-SAF Total Symptom Score as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary endpoint: symptom assessment and averaging period

> “14-day average of patient-reported severity of 11 symptoms”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Randomized analysis: treatment-group counts

| Group | Participants |
| --- | --- |
| Avapritinib | “n=141” |
| Placebo | “n=71” |

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### FDA label analysis: missing continuous symptom-score observations

> “Markov chain Monte Carlo simulation was used to impute the missing values at Baseline or C7D1.”

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Long-term analysis across PIONEER study parts

> “226 patients initiated avapritinib at 25 mg QD.”

Source: [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Avapritinib group: baseline characteristics in the FDA label

| Characteristic | Value |
| --- | --- |
| Median age, years | “50” |
| Female, percent | “71%” |
| Mean TSS | “50.17” |

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Comparator avapritinib, PIONEER trial: week 24 total symptom score, avapritinib

> “a decrease of 15.6 points (95% CI, −18.6 to −12.6)”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="topic-3.1.2.8.3-2"></a>

###### Comparator avapritinib, PIONEER trial: week 24 total symptom score, placebo

> “a decrease of 9.2 points (−13.1 to −5.2)”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="topic-3.1.2.8.3-3"></a>

###### Comparator avapritinib, PIONEER trial: abstract-reported statistical significance

> “From baseline to week 24, avapritinib-treated patients had a decrease of 15.6 points (95% CI, −18.6 to −12.6) in TSS compared to a decrease of 9.2 points (−13.1 to −5.2) in the placebo group; P<0.003.”

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/)

<a id="topic-3.1.2.8.3-4"></a>

###### FDA label analysis: week 24 absolute mean TSS change

| Avapritinib plus BSC | Placebo plus BSC | Two-sided p-value |
| --- | --- | --- |
| “-15.33” | “-9.64” | “0.012” |

Source: [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### PIONEER Part 2: MC-QoL at cycle 7, day 1

| Measure | Avapritinib plus BSC | Placebo plus BSC |
| --- | --- | --- |
| Mean change from baseline | “−19.2” | “−9.55” |

Source: [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### PIONEER Part 2: edema events

| Measure | Avapritinib plus BSC | Placebo plus BSC |
| --- | --- | --- |
| Participants with at least one edema adverse event | “25.5%” | “11.3%” |

Source: [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)

<a id="topic-3.1.2.8.5-2"></a>

###### PIONEER Part 2: anaphylaxis treated with epinephrine after baseline

| Avapritinib plus BSC | Placebo plus BSC |
| --- | --- |
| “2” | “3” |

Source: [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)

<a id="topic-3.1.2.8.5-3"></a>

###### Comparator avapritinib, PIONEER long-term follow-up

> “Serious TRAEs occurred in 3 patients (1%), and 7 patients (3%) discontinued treatment because of TRAEs.”

Source: [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

PIONEER evaluates avapritinib, not bezuclastinib, in moderate-to-severe ISM. Its results do not provide a head-to-head comparison of the two drugs. The publication and FDA label report different numerical TSS analyses, which are preserved separately. Long-term Part 3 is open-label. The Canadian appraisal reports only two versus three post-baseline anaphylaxis events treated with epinephrine, limiting the precision of conclusions about that outcome.

Source: [Gotlib et al. (2023)](https://research.uni-luebeck.de/en/publications/avapritinib-versus-placebo-in-indolent-systemic-mastocytosis/); [AYVAKIT prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf); [Akin et al. (2026b)](https://portal.findresearcher.sdu.dk/en/publications/avapritinib-achieves-long-term-disease-control-with-favorable-saf/); [Canada’s Drug Agency avapritinib reimbursement recommendation (2026)](https://www.ncbi.nlm.nih.gov/books/NBK624169/)

<a id="heading-3.1.3"></a>

#### 3.1.3 WO2024138005A1 Example 7

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Formulation comparison objective

> “pharmacokinetics and relative bioavailability”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

No evidence found.

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Single-center crossover formulation comparison

> “single-center, open-label, 2-period, randomized, crossover”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Study population

> “healthy adult subjects”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Single-dose cohorts for formulations A and B

| Cohort | Dose |
| --- | --- |
| 1 | “50 mg” |
| 2 | “300 mg” |
| 3 | “600 mg” |

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Pharmacokinetics and Relative Bioavailability as the Study Endpoints

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Participants receiving the three initial dose levels

> “Thirty subjects (10/cohort)”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Pharmacokinetic results: absorption

> “Bezuclastinib was slowly absorbed after oral administration, reaching median time to maximum concentration 12 to 16 hours post dose.”

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

Additional sources: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

The formulation comparison included 30 healthy-adult participants in a single-center, open-label crossover study. These single-dose pharmacokinetic observations do not establish efficacy or long-term safety in nonadvanced SM. The source does not disclose a trial acronym or protocol number; the study is identified here by the patent's Example 7.

Source: [Patent WO2024138005A1 (2024)](https://patents.google.com/patent/WO2024138005A1/en)

## Related pages
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Terms and abbreviations](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations.md)
- [Bezuclastinib: Nonadvanced systemic mastocytosis](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/executive-summary.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Product information and disease description](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: Economic information and modeling report](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economics.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: References](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: prevalence by geography](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/prevalence.md)
- [Bezuclastinib in Nonadvanced systemic mastocytosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/cost-effectiveness-analyses.md)
